Viking Therapeutics Inc (VKTX) (Q2 2026) Earnings Call Highlights: Advancing Obesity Pipeline
GuruFocus News
Thu, July 30, 2026 at 10:33 AM GMT+5:30
6 min read
- VKTX
-1.27%
This article first appeared on GuruFocus
Net Loss (Q2 2026): $128.1 million, or $1.10 per share, compared to a net loss of $65.6 million, or $0.58 per share, in Q2 2025
Net Loss (Six Months Ended June 30, 2026): $286.5 million, or $2.47 per share, compared to a net loss of $111.2 million, or $0.99 per share, in the same period of 2025
Research and Development (R&D) Expenses (Q2 2026): $115.8 million, compared to $60.2 million in Q2 2025
R&D Expenses (Six Months Ended June 30, 2026): $266 million, compared to $101.5 million in the same period of 2025
General and Administrative (G&A) Expenses (Q2 2026): $16.9 million, compared to $14.4 million in Q2 2025
G&A Expenses (Six Months Ended June 30, 2026): $30.9 million, compared to $28.5 million in the same period of 2025
Cash, Cash Equivalents, and Short-Term Investments: $502 million as of June 30, 2026, compared to $706 million as of December 31, 2025
Is VKTX fairly valued? Test your thesis with our free DCF calculator
Release Date: July 29, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript
Positive Points
VK2735 Phase III VANQUISH program is fully enrolled and advancing on track, with both obesity and obesity/type 2 diabetes trials progressing
Oral VK2735 Phase III trials expected to initiate in Q4 2026, positioning it as a potential first-to-market oral dual GLP-1/GIP agonist
Novel maintenance dosing study for VK2735 is nearing completion, with results expected later this quarter, exploring less frequent dosing regimens
New dual amylin and calcitonin receptor agonist, VK3019, entered Phase I clinical development, expanding the obesity pipeline
Strong balance sheet with over $500 million in cash, expected to fund key milestones including completion of Phase III trials
Key executive hires, including a Chief Commercial Officer and Chief Medical Officer, strengthen commercial and clinical leadership
Negative Points
Net loss increased significantly to $128.1 million in Q2 2026 from $65.6 million in Q2 2025, driven by higher R&D expenses
Cash and short-term investments decreased to $502 million from $706 million at year-end 2025, reflecting high cash burn
Phase III oral VK2735 trial design details remain undisclosed, creating uncertainty about dosing and enrollment targets
Maintenance study results may be difficult to compare with competitor trials due to different study designs and shorter duration
Early-stage VK3019 program faces uncertainty, with no clear go/no-go decision criteria until Phase I MAD data in 2027
